-
My Account
My Account
As on 18 Jan, 2021 | 03:28
As on --
(OI , PRICE )
As on --
| Open | 3,640.00 |
| Previous Close | 3,644.80 |
| UC Limit | 4,009.25 |
| LC Limit | 3,280.35 |
| Volume | 946,008.00 |
| VWAP | 3,593.68 |
| Mkt Cap (Rs. Cr.) | 94,454 |
| 20D Avg Volume | 812,145 |
| 20D Avg Delivery | 315,520 |
| Beta | 0.570.52 |
| Face Value | 2.00 |
| TTM EPS | 66.26 |
| TTM PE | 53.70 |
| Sector PE | 40.86 |
| Book Value Per Share | 275.36 |
| P/B | 12.93 |
| Dividend Yield | 0.45 |
| P/C | 48.56 |
Strong Performer: Stock with consistent financial performance, quality management, and strong technical momentum indicating good investor enthusiasm. Currently valued at Good to expensive valuation
indicates Average Financials
| Revenue | 10.5% |
| NetProfit | 9.1% |
| OperatingProfit | 8.0% |
| R1 | R2 | R3 | PP | S1 | S2 | S3 | |
|---|---|---|---|---|---|---|---|
| Classic | - - | - - | - - | - - | - - | - - | - - |
| Fibonacci | - - | - - | - - | - - | - - | - - | - - |
| Camarilla | - - | - - | - - | - - | - - | - - | - - |
Note : Support and Resistance level for the day, calculated based on price range of the previous trading day.
| R1 | - - | Pivot - - |
S1 | - - |
| R2 | - - | S2 | - - | |
| R3 | - - | S3 | - - |
Note : Support and Resistance level for the day, calculated based on price range of the previous trading day.
| Days | |
|---|---|
| 5 | - - |
| 10 | - - |
| 20 | - - |
| 50 | - - |
| 100 | - - |
| 200 | - - |
| Type | R1 | R2 | R3 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | - - | - - | - - | - - | - - | - - | - - |
| Fibonacci | - - | - - | - - | - - | - - | - - | - - |
| Camarilla | - - | - - | - - | - - | - - | - - | - - |
Note : Support and Resistance level for the week, calculated based on price range of the previous trading week.
| R1 | - - | Pivot - - |
S1 | - - |
| R2 | - - | S2 | - - | |
| R3 | - - | S3 | - - |
Note : Support and Resistance level for the week, calculated based on price range of the previous trading week.
| Days |
|---|
| Type | R1 | R2 | R3 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | - - | - - | - - | - - | - - | - - | - - |
| Fibonacci | - - | - - | - - | - - | - - | - - | - - |
| Camarilla | - - | - - | - - | - - | - - | - - | - - |
Note : Support and Resistance level for the month, calculated based on price range of the previous trading month.
| R1 | - - | Pivot - - |
S1 | - - |
| R2 | - - | S2 | - - | |
| R3 | - - | S3 | - - |
Note : Support and Resistance level for the month, calculated based on price range of the previous trading month.
| Days |
|---|
| 1 Week | --% | |
| 1 Month | --% | |
| 3 Months | --% | |
| YTD | --% | |
| 1 Year | --% | |
| 3 Years | --% |
Divis Labs share price hits 52-week high after Q2 profit jumps 45% Nov 09 2020 09:11 AM
Divi's Laboratories Q2 net profit up 46% at Rs 520 crore Nov 07 2020 04:11 PM
These five API companies may benefit as drugmakers seek to reduce dependence on Chinese raw material Aug 28 2020 04:08 PM
SBI Life, Divis Labs to replace Bharti Infratel, ZEE in Nifty50 Aug 20 2020 08:08 PM
Bulls sang the same song in 2016 , Pedigree of regulations hammered it to 30 percent low .It will go at this pace of tanking next five years China is back on action .Nothing overly speculated stands brother View more | 4
Posted by : Jackvarg
Start accumulating Divis lab for target of Rs. 3700/- View more
Posted by : surajp21
Short term you are winner by shorting but I know Divis Labs has a strong pedigree and will bounce back for 4000/5000.Just wait and watch.Bears will be wiped out View more | 4
Posted by : Darshan2020
| Qty 35151 | Price 3718.9 | % Traded 0.01 |
| Qty 35151 | Price 3718.9 | % Traded 0.01 |
| Qty 1129113 | Price 635 | % Traded 0.43 |
| Qty 1129113 | Price 635 | % Traded 0.43 |
| Qty 100191 | Price 896 | % Traded 0.04 |
| Qty 100191 | Price 896 | % Traded 0.04 |
*Transaction of a minimum quantity of 500,000 shares or a minimum value of Rs 5 crore.
| Qty 1886001 | Price 1438.98 | % Traded 0.71 |
| Qty 1454375 | Price 1047.17 | % Traded 0.55 |
| Qty 2285198 | Price 582.12 | % Traded 0.86 |
| Qty 2373622 | Price 582.9 | % Traded 0.89 |
| Qty 955020 | Price 1194.11 | % Traded 0.36 |
| Qty 698683 | Price 1188.73 | % Traded 0.26 |
*A bulk deal is a trade where total quantity of shares bought or sold is more than 0.5% of the equity shares of a company listed on the exchange.
| Qty 300 | Price 3785.45 | % Traded 0.00 | Post Tnx Hold. 0% |
| Qty 300 | Price 3765.1 | % Traded 0.00 | Post Tnx Hold. 0% |
| Qty 0 | Price 0 | % Traded 0.00 | Post Tnx Hold. 0% |
| Qty 0 | Price 0 | % Traded 0.00 | Post Tnx Hold. 0% |
| Qty 0 | Price 0 | % Traded 0.00 | Post Tnx Hold. 0% |
| Qty 3 | Price 3076 | % Traded 0.00 | Post Tnx Hold. 0% |
*Disclosures under SEBI Prohibition of Insider Trading Regulations, 2015
| Qty 83580 | Price 0 | % Traded 0.03 | Post Tnx Hold. 3.01% |
| Qty 8000000 | Price 0 | % Traded 3.01 | Post Tnx Hold. 20.34% |
| Qty 8000000 | Price 0 | % Traded 3.01 | Post Tnx Hold. 2.85% |
| Qty 188637 | Price 0 | % Traded 0.07 | Post Tnx Hold. 5.05% |
| Qty 344000 | Price 0 | % Traded 0.12 | Post Tnx Hold. 5.02% |
*Disclosures under SEBI SAST (Substantial Acquisition of Shares and Takeovers) Regulations, 2011
| Date | Agenda |
|---|
| Ex-Date | Type | Dividend (%) |
|---|
| Announcement Date | Ex-Bonus | Ratio |
|---|
| Ex-Split | Old FV | New FV |
|---|
| Ex-Right | Ratio | Premium |
|---|
| Date | Agenda |
|---|
| Company Name | Price | % Chg | MCap | TTM PE | P/B | ROE | 1 Yr Perform | Net Profit | Net Sales | Debt to Equity |
|---|---|---|---|---|---|---|---|---|---|---|
| Divis Labs | 3559.20 | -2.35 | 94485.58 | 53.74 | 12.91 | 18.76 | 87.00 | 1,372 | 5,310 | 0.00 |
| Sun Pharma | 579.60 | -4.09 | 139065.45 | 83.28 | 2.83 | 8.31 | 27.50 | 4,186 | 32,837 | 0.17 |
| Dr Reddys Labs | 5043.00 | -3.26 | 83864.14 | 52.12 | 5.38 | 12.98 | 66.20 | 1,969 | 17,517 | 0.11 |
| Cipla | 798.65 | -3.04 | 64407.55 | 35.00 | 4.01 | 9.81 | 66.28 | 1,546 | 17,131 | 0.18 |
| Aurobindo Pharm | 911.95 | -2.57 | 53434.67 | 17.01 | 3.18 | 16.84 | 87.66 | 2,844 | 23,098 | 0.32 |
Your feedback matters! Tell us what we got right and what we didn’t? Click here>
